MCA-derived MSCs inhibit cell damage, tissue damage and improve peripheral blood flow following hindlimb ischemic injury in miceLikeFollowShareRead full articlehttps://www.isct-cytotherapy.org/article/S1465-3249(15)01107-X/abstractShare your feedbackQuestions (0)Post questionYour question will be sent privately to Cynata Therapeutics. The company may choose to make this question public.Start the conversationAsk Cynata Therapeutics a question about this update.DiscoverShare your feedbackDiscover
